Catalio Capital Management Launches Long-Short Public Equities Strategy Focused on Global Healthcare and Life Sciences Sectors

Catalio Capital Management, LP ("Catalio"), a leading multi-strategy life sciences investment firm with more than $1 billion in assets under management, today announced the launch of its dedicated public equities hedge fund investment strategy focused on identifying compelling life science investment opportunities globally. In connection with the launch of the vehicle, the seasoned investment team from HealthCor Management ("HealthCor"), a well-established healthcare hedge fund with a two-decade track record, along with key members of its operations, financial, administrative and marketing divisions, have agreed to join Catalio to help build out the strategy.

"When we launched Catalio Capital Management as a life sciences investment firm, we did so with two foundational objectives in mind: to bring breakthrough biomedical technologies to patients and to deliver outstanding returns to our investors. Our intention has always been to build a multi-strategy platform with three pillars ? private equity, private credit, and public equities ? so that we can support compelling life science investment opportunities at all stages of development," said George Petrocheilos, Co-Founder and Managing Partner of Catalio. "Launching Catalio's Public Equities strategy and adding experienced public equities investors to our team will significantly augment our capabilities in support of this goal and complement our robust private equity, credit, and special situations strategies. We welcome our newest teammates and look forward to continuing to enhance our platform."

In building its public equities strategy, Catalio selected HealthCor, founded in 2005, because of its track record in identifying mispriced global healthcare and life science equity securities and delivering strong, risk-adjusted returns to investors. HealthCor's talented team, disciplined and fundamentals-based approach to portfolio management, and deep knowledge of public healthcare markets will help grow Catalio's Public Equities strategy and enable Catalio to capitalize on unique opportunities across broader global healthcare markets. HealthCor's founders, Art Cohen and Joe Healey, both long-time supporters and early investors in Catalio, will join the firm as Senior Advisors.

"Today's life science markets are rapidly evolving, and scale, experience, and execution matter more than ever. We believe that adding HealthCor's team meaningfully enhances Catalio's investing and researching capabilities and further positions the firm to continue to identify and execute high-quality, differentiated investments across life science markets," said Dr. Jacob Vogelstein, Co-Founder and Managing Partner of Catalio. "HealthCor's team brings an impressive track record across cycles, and we are thrilled to have them on board."

The launch of its public equities strategy represents another substantial milestone for Catalio following the successful close of Catalio's ~$400 million Catalio Nexus Fund III, which has already made investments in more than twenty leading biotech companies; the successful launch of the Structured Opportunities Fund, ahead of demand for structured credit and venture debt; and the opening of new headquarters in New York on the High Line and two additional offices, in Baltimore, near Johns Hopkins Medicine and in London, on Baker Street.

About Catalio Capital Management
Catalio Capital Management, LP, is a multi-strategy life sciences investment firm that focuses on breakthrough biomedical technology companies developing the next generation of drugs, devices, diagnostics, and data-driven insights. Catalio's Partnership includes over 39 world-renowned scientists with extensive academic and scientific achievements who have each started well-established companies based on their research. Catalio has offices in New York, Baltimore, and London.

For more information, visit www.cataliocapital.com.